Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

Published:2018-07 Issue:7 Volume:5 Page:e366-e378
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Bekker Linda-Gail,Moodie Zoe,Grunenberg Nicole,Laher Fatima,Tomaras Georgia D,Cohen Kristen W,Allen Mary,Malahleha Mookho,Mngadi Kathryn,Daniels Brodie,Innes Craig,Bentley Carter,Frahm Nicole,Morris Daryl E,Morris Lynn,Mkhize Nonhlanhla N,Montefiori David C,Sarzotti-Kelsoe Marcella,Grant Shannon,Yu Chenchen,Mehra Vijay L,Pensiero Michael N,Phogat Sanjay,DiazGranados Carlos A,Barnett Susan W,Kanesa-thasan Niranjan,Koutsoukos Marguerite,Michael Nelson L,Robb Merlin L,Kublin James G,Gilbert Peter B,Corey Lawrence,Gray Glenda E,McElrath M Juliana

Funder

National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases

Fred Hutchinson Cancer Research Center

NIH/NIAID

Bill & Melinda Gates Foundation

Sanofi Pasteur

US Army

NIAID

NIAID US Public Health Service

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference33 articles.

1. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection;Flynn;J Infect Dis,2005

2. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand;Pitisuttithum;J Infect Dis,2006

3. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial;Buchbinder;Lancet,2008

4. Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study;Gray;Lancet Infect Dis,2011

5. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand;Rerks-Ngarm;N Engl J Med,2009

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A follow-up study: 6-year cART-free virologic control of rhesus macaques after PD-1-based DNA vaccination against pathogenic SHIV _SF162P3CN challenge;Microbiology Spectrum;2023-12-12

2. Conjugation of HIV-1 envelope to hepatitis B surface antigen alters vaccine responses in rhesus macaques;npj Vaccines;2023-11-24

3. Contemporary HIV-1 consensus Env with redesigned hypervariable loops promote antibody binding;2023-11-19

4. Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120;The Journal of Infectious Diseases;2023-10-05

5. A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses;Science Translational Medicine;2023-05-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3